A Prospective Observational Study to Assess the Efficacy of a SGLT2 Inhibitor (Dapagliflozin) in Kidney Allograft Recipients with Diabetes Mellitus

被引：0
|
作者：
Naskar, Avishek [1 ]
机构：
[1] Kolkata Kidney Inst, Kolkata, West Bengal, India
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2024年 / 35卷 / 10期
关键词：
D O I：
10.1681/ASN.2024ej3cxwcq
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
TH-PO741
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
    Huang, Yuxin
    Jiang, Zeju
    Wei, Yiping
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [42] SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
    Megan Leila Baker
    Mark Anthony Perazella
    Journal of Nephrology, 2020, 33 : 985 - 994
  • [43] SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
    Baker, Megan Leila
    Perazella, Mark Anthony
    JOURNAL OF NEPHROLOGY, 2020, 33 (05) : 985 - 994
  • [44] The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
    Weir, Matthew R.
    POSTGRADUATE MEDICINE, 2016, 128 (03) : 290 - 298
  • [45] SGLT2 inhibitor alleviates hypomagnesemia in patients with chronic kidney disease: a retrospective observational study
    Osawa, Kosuke
    Ohya, Masaki
    Yamamoto, Shuto
    Nakashima, Yuri
    Tanaka, Yusuke
    Yamano, Yukiko
    Takatsuka, Taisuke
    Araki, Shin-Ichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [46] SGLT2 inhibitor alleviates hypomagnesemia in patients with chronic kidney disease: a retrospective observational study
    Osawa, Kosuke
    Ohya, Masaki
    Yamamoto, Shuto
    Nakashima, Yuri
    Tanaka, Yusuke
    Yamano, Yukiko
    Takatsuka, Taisuke
    Araki, Shin-Ichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I1976 - I1977
  • [47] Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
    Rodrigues, E. A.
    Dionizio, A.
    Rosa, C. M.
    Campos, D. H. S.
    Damatto, F. C.
    Borim, P. A.
    Pagan, L. U.
    Oliveira, J. P. G.
    Souza, L. M.
    Gatto, M.
    Araujo, T. T.
    Buzalaf, M. A.
    Cunha, T. M.
    Okoshi, K.
    Okoshi, M. P.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [48] Short term effect of SGLT2 inhibitor, Dapagliflozin added on to standard therapy in decompensated heart failure patients with diabetes mellitus
    Nakagaito, M.
    Joho, S.
    Ushijima, R.
    Nakamura, M.
    Hirai, T.
    Kinugawa, K.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1030 - 1030
  • [49] The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure
    Berezin, Alexander A.
    Obradovic, Zeljko
    Fushtey, Ivan M.
    Berezina, Tetiana A.
    Novikov, Evgen V.
    Schmidbauer, Lukas
    Lichtenauer, Michael
    Berezin, Alexander E.
    BIOMEDICINES, 2023, 11 (02)
  • [50] Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
    Abdul-Ghani, Muhammad A.
    Norton, Luke
    DeFronzo, Ralph A.
    CURRENT DIABETES REPORTS, 2012, 12 (03) : 230 - 238
12345